Low-dose LBH589 increases the sensitivity of cisplatin to cisplatin-resistant ovarian cancer cells

被引:15
作者
Ma, Yen-Ying [2 ,3 ]
Lin, Hao [2 ,3 ]
Moh, Jau-Sung [4 ]
Chen, Kuang-Den [5 ]
Wang, I-Wen [2 ]
Ou, Yu-Che [2 ,3 ]
You, Ying-Shu [1 ]
Lung, Chia-Chi [1 ]
机构
[1] Chung Shan Med Univ, Dept Publ Hlth, Taichung 402, Taiwan
[2] Chang Gung Univ, Coll Med, Dept Obstet & Gynecol, Chang Gung Mem Hosp,Kaohsiung Med Ctr, Kaohsiung, Taiwan
[3] Chang Gung Mem Hosp, Kaohsiung Chang Gung Canc Ctr, Kaohsiung, Taiwan
[4] Fortune Inst Technol, Kaohsiung, Taiwan
[5] Chang Gung Univ, Coll Med, Ctr Translat Res Biomed Sci, Chang Gung Mem Hosp,Kaohsiung Med Ctr, Kaohsiung, Taiwan
来源
TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY | 2011年 / 50卷 / 02期
关键词
Cisplatin; Drug resistance; LBH589; Ovarian cancer; Sensitivity; HISTONE DEACETYLASE INHIBITORS; DRUG-RESISTANCE; IN-VIVO; GENE-EXPRESSION; CARCINOMA CELLS; HDAC INHIBITORS; LEUKEMIA-CELLS; GROWTH-FACTOR; CIS-DIAMMINEDICHLOROPLATINUM(II); DEMETHYLATION;
D O I
10.1016/j.tjog.2011.01.022
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: There is a need to develop alternative therapeutic strategies to overcome cisplatin-associated resistance in patients with ovarian cancer. Histone deacetylation (HDAC) associated with inactivation of genes has been implicated in the epigenetic silencing of tumor suppressor genes affecting critical biological activities in cancer cells and may be an important factor in acquired cisplatin-associated resistance. In this report, we tested a combination of cisplatin and LBH589 (histone deacetylation inhibitor) in cisplatin-resistant ovarian cancer cells to explore the reversal effect of cisplatin resistance and changes of gene expression. Materials and Methods: To detect the synergistic effects of antiproliferation between cisplatin and LBH589 in ovarian cancer cells, we performed a cell viability assay and a clonogenic assay. To investigate the differences of gene expression between cells treated by cisplatin alone and cotreated with cisplatin and LBH589, a microarray mRNA analysis was performed. Results: In the presence of low-dose LBH589, the inhibition concentration value of cisplatin for A2780-cp70 cells was much lower than with cisplatin treatment alone. Gene expression profiles identified that a total of 354 genes had been significantly upregulated and a total of 63 genes been downregulated with LBH589 cotreatment. Conclusion: We hypothesized that combination of cisplatin and LBH589 can override cisplatin-associated resistance in ovarian cancer cells. These results provide initial evidence for testing this combination in clinical use. Copyright (C) 2011, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
引用
收藏
页码:165 / 171
页数:7
相关论文
共 34 条
[1]   Ovarian cancer: Strategies for overcoming resistance to chemotherapy [J].
Agarwal, R ;
Kaye, SB .
NATURE REVIEWS CANCER, 2003, 3 (07) :502-516
[2]   The therapeutic potential of hepatocyte growth factor to sensitize ovarian cancer cells to cisplatin and paclitaxel in vivo [J].
Bardella, Chiara ;
Dettori, Daniela ;
Olivero, Martina ;
Coltella, Nadia ;
Mazzone, Massimiliano ;
Di Renzo, Maria Flavia .
CLINICAL CANCER RESEARCH, 2007, 13 (07) :2191-2198
[3]   Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group [J].
Beckers, Thomas ;
Burkhardt, Carmen ;
Wieland, Heike ;
Gimmnich, Petra ;
Ciossek, Thomas ;
Maier, Thomas ;
Sanders, Karl .
INTERNATIONAL JOURNAL OF CANCER, 2007, 121 (05) :1138-1148
[4]   Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells [J].
Edwards, Arthur ;
Li, Jiannong ;
Atadja, Peter ;
Bhalla, Kapil ;
Haura, Eric B. .
MOLECULAR CANCER THERAPEUTICS, 2007, 6 (09) :2515-2524
[5]   Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma [J].
Ellis, Leigh ;
Pan, Yan ;
Smyth, Gordon K. ;
George, Daniel J. ;
McCormack, Chris ;
Williams-Truax, Roxanne ;
Mita, Monica ;
Beck, Joachim ;
Burris, Howard ;
Ryan, Gail ;
Atadja, Peter ;
Butterfoss, Dale ;
Dugan, Margaret ;
Culver, Kenneth ;
Johnstone, Ricky W. ;
Prince, H. Miles .
CLINICAL CANCER RESEARCH, 2008, 14 (14) :4500-4510
[6]   The histone deacetylase inhibitors LAQ824 and LBH589 do not require death receptor signaling or a functional apoptosome to mediate tumor cell death or therapeutic efficacy [J].
Ellis, Leigh ;
Bots, Michael ;
Lindemann, Ralph K. ;
Bolden, Jessica E. ;
Newbold, Andrea ;
Cluse, Leonie A. ;
Scott, Clare L. ;
Strasser, Andreas ;
Atadja, Peter ;
Lowe, Scott W. ;
Johnstone, Ricky W. .
BLOOD, 2009, 114 (02) :380-393
[7]   Histone deacetylase inhibitors: Apoptotic effects and clinical implications [J].
Emanuele, Sonia ;
Lauricella, Marianna ;
Tesoriere, Giovanni .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2008, 33 (04) :637-646
[8]   Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells [J].
Fazzone, William ;
Wilson, Peter M. ;
LaBonte, Melissa J. ;
Lenz, Heinz-Josef ;
Ladner, Robert D. .
INTERNATIONAL JOURNAL OF CANCER, 2009, 125 (02) :463-473
[9]   Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients [J].
Ferrandina, G ;
Lauriola, L ;
Zannoni, GF ;
Fagotti, A ;
Fanfani, F ;
Legge, F ;
Maggiano, N ;
Gessi, M ;
Mancuso, S ;
Ranelletti, FO ;
Scambia, G .
ANNALS OF ONCOLOGY, 2002, 13 (08) :1205-1211
[10]   Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells [J].
Fiskus, Warren ;
Pranpat, Michael ;
Bali, Purva ;
Balasis, Maria ;
Kumaraswamy, Sandhya ;
Boyapalle, Sandhya ;
Rocha, Kathy ;
Wu, Jie ;
Giles, Francis ;
Manley, Paul W. ;
Atadja, Peter ;
Bhalla, Kapil .
BLOOD, 2006, 108 (02) :645-652